Astec LifeSciences Limited — Others, 04-07-2025: Shareholders meeting

Astec LifeSciences has announced a board meeting to approve the financial results for the quarter and half-year. The company reported a challenging FY 2024-25 with revenues declining to ₹386.93 Cr from ₹463.82 Cr and a loss after tax widening to ₹134.71 Cr from ₹46.89 Cr a year earlier. This was due to subdued global agrochemical demand, price and volume pressures, high-cost raw material inventory, and lower volumes in both Enterprise and CDMO segments. Export sales fell 21.1%, domestic sales declined 8.1%, and gross margin dropped to 22.1% from 30.3%. The company is focused on increasing volumes, cost optimization, and leveraging its advanced R&D center for future CDMO growth. Godrej Agrovet continues as the major shareholder with 64.75% stake. The Annual General Meeting will be held via video conferencing with details on e-voting and dividend transfer to the Investor Education and Protection Fund in accordance with legal provisions. The Board recommends reappointment of Mr. Nadir B. Godrej as a Director and the reappointment of cost and secretarial auditors. Related party transactions up to ₹400 Cr with Godrej Agrovet (holding company) for FY 2025-26 are proposed for shareholder approval. The company remains committed to sustainability, safety, and community welfare through initiatives like the bamboo development project benefiting over 10,000 farmers and other CSR programs. Financial policies, risk management, and governance comply with applicable laws and SEBI regulations.